GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of Neisseria meningitidis – A, B, C, W, and Y – which commonly cause invasive meningococcal disease, the company noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- GSK shares shorted by leading U.S. hedge fund, The Times reports
- Balanced Risk-Reward Outlook for GSK Amid Modest Growth and Market Challenges
- GSK initiated with an Equal Weight at Morgan Stanley
- GSK price target raised to 1,500 GBp from 1,440 GBp at JPMorgan